Bristol-Myers Squibb GmbH & Co. KGaA

Arnulfstr. 29 | 80636 München

Tel.: +49 89 1 21 42-0

www.bms-onkologie.de

 

Ausgewählte Pressemitteilungen

Nivolumab Plus Ipilimumab Combination Demonstrated Superior Overall Survival

Quelle: © Bristol-Myers-Squibb

10.09.2017 - Pressemitteilung der Bristol-Myers Squibb GmbH & Co. KGaA 
Nivolumab plus Ipilimumab reduced the risk of death by 37% versus standard of care, Sunitinib, in intermediate- and poor-risk patients. The combination also significantly improved overall survival in all randomized patients.  

Weiterlesen

CheckMate -214 Study Evaluating Nivolumab in Combination with Ipilimumab Stopped Early for Demonstrating Overall Survival Benefit

Quelle: © Bristol-Myers-Squibb

07.09.2017 - Pressemitteilung der Bristol-Myers Squibb GmbH & Co. KGaA 
Nivolumab plus Ipilimumab showed superior overall survival versus current standard of care sunitinib in intermediate- and poor-risk patients, a co-primary endpoint. The combination also met the secondary endpoint of improved overall survival in all randomized patients

Weiterlesen

Themen: